IP Library Granted Patent US 10,611,760
Granted Patent B2
US 10,611,760 · App. 15/508,392 · Granted Apr 7, 2020

Therapeutic compounds as inhibitors of the orexin-1 receptor

Inventors: Emma Louise Blaney (Manchester, GB); Barrie Phillip Martin (Manchester, GB); Thorsten Nowak (Manchester, GB); Martin John Watson (Manchester, GB)
Assignee: C4X Discovery Limited
C07D471/04C07C233/69C07C233/78C07C275/28C07C275/40C07D213/63C07D213/64C07D213/74C07D231/38C07D235/26C07D235/30C07D239/34C07D239/42C07D239/80C07D239/84C07D401/12C07D401/14C07D403/12C07D413/12C07D413/14C07D417/12C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,611,760
App. No.
15/508,392
Granted
Apr 7, 2020
Kind
B2
Abstract

The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

Claims (138)

1. A compound of formula IA:

wherein:

R b is selected from:

i. (1-4C)alkyl which is optionally substituted by one or more fluor;

ii. (3-6C)cycloalkyl which is optionally substituted by one or more fluoro; or

iii. (3-6C)cycloalkyl(1-2C)alkyl which is optionally substituted by one or more fluoro;

Ar is aryl or heteroaryl, each of which is optionally substituted with one or more substituents selected from halo, cyano, nitro or a group of the formula:

-L 1 -X 1 —R 6

wherein

L 1 is absent or a linker group of the formula —[CR 7 R 8 ] r — in which r is an integer selected from 1, 2, 3 or 4, and R 7 and R 8 are each independently selected from hydrogen, halo, hydroxy or a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 7 and R 8 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 1 is absent or selected from —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 9 )—, —N(R 9 )—C(O)—, —C(O)—N(R 9 )—, —N(R 9 )—C(O)O—, —OC(O)—N(R 9 )—, —N(R 9 ) C(O)N(R 10 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 9 )—, —N(R 9 )SO 2 — or —S(O)(═NR 10 )—, wherein R 9 and R 10 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl, and

R 6 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, aryl(1-2C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl-(1-2C)alkyl, heteroaryl, or heteroaryl-(1-2C)alkyl,

and wherein R 6 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, or a group of the formula:

-L 2 -X 2 —R 11

wherein

L 2 is absent or a linker group of the formula —[CR 12 R 13 ] s — in which s is an integer selected from 1, 2, 3 or 4, and R 12 and R 13 are each independently selected from hydrogen or a (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents, or R 12 and R 13 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 2 is absent or selected from —O—, —C(O)—, —C(O)O—, —OC(O)—, —N(R 14 )—, —N(R 14 )—C(O)—, —C(O)—N(R 14 )—, —N(R 14 )—C(O)O—, —OC(O)—N(R 14 )—, —N(R 14 )C(O)N(R 15 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 14 )—, —N(R 14 )SO 2 —or —S(O)(═NR 14 )—, wherein R 14 and R 15 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl; and

R 11 is hydrogen or a (1-6C)alkyl (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents; and

R z2 is selected from halo, cyano, nitro, or a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, or —SO 2 —, wherein R 33 is selected from hydrogen or (1-2C)alkyl; and

R 30 is hydrogen, (1-4C)alkyl, (3-4C)cycloalkyl, (3-4C)cycloalkyl(1-2C)alkyl, 3-6-membered heterocyclyl, 3-6-membered heterocyclyl-(1-2C)alkyl, 5-6-membered heteroaryl, or 5-6-membered heteroaryl-(1-2C)alkyl,

and wherein R 30 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, or a group of the formula:

-L 4 -X 4 —R 35

wherein

L 4 is absent or a linker group of the formula —[CR 36 R 37 ] u — in which u is an integer selected from 1, 2 or 3, and R 36 and R 37 are each independently selected from hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more fluoro substituents; or R 36 and R 37 are optionally linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring which is optionally substituted by one or more fluoro substituents;

X 4 is absent or selected from —O—, —C(O)—, —N(R 38 )—, —N(R 38 )—C(O)—, —C(O)—N(R 38 )—, —N(R 38 )C(O)N(R 39 )—, —S—, —SO—, —SO 2 —, —S(O) 2 N(R 38 )—, —N(R 38 )SO 2 — or —S(O)(═NR 38 )—, wherein R 38 and R 39 are selected from hydrogen, (1-4C)alkyl, (1-4C)fluoroalkyl or (3-6C)cycloalkyl; and

R 35 is hydrogen or a (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl group which is optionally substituted by one or more fluoro substituents;

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 , wherein

R b is (1-4C)alkyl optionally substituted by one or more fluoro;

R z2 is selected from halo, cyano, nitro, and a group of the formula:

-L 3 -X 3 —R 30

wherein

L 3 is absent;

X 3 is absent, or selected from —O—, —N(R 33 )—, —N(R 33 )—C(O)—, —C(O)—N(R 33 )—, —S—, —SO—, or —SO 2 —, wherein R 33 is hydrogen or (1-2C)alkyl; and

R 30 is hydrogen or (1-4C)alkyl; and wherein R 30 is optionally further substituted by one or more fluoro atoms.

3. A compound according to claim 2 , wherein

R b is methyl optionally substituted by one or more fluoro;

R z2 is halo, methyl, methoxy, CF 3 or OCF 3 ; and

Ar is pyridyl, pyrmidinyl, pyrazinyl, which is optionally substituted by one or more substituent groups selected from halo, cyano, hydroxyl, mercapto, amino, carbamoyl, sulphamoyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy, (1-2C)haloalkoxy, (1-2C)alkylamino, di-[(1-2C)alkyl]amino, (1-2C)alkylthio, (1-2C)alkylsulphinyl, (1-2C)alkylsulphonyl, (1-2C)alkoxycarbonyl, N-(1-2C)alkylcarbamoyl, N,N-di-[(1-2C)alkyl]carbamoyl, (2C)alkanoyl, (2C)alkanoyloxy, (2C)alkanoylamino, N-(1-2C)alkylsulphamoyl and N,N-di-[(1-2C)alkyl]sulphamoyl.

4. A compound which is selected from:

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,5-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-2-methyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-2-methyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-4-methylpentan-2-yl)-N,2-dimethyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethyl-4-phenylthiazole-5-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3,3-dimethylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(2-((5-chloropyridin-2-yl)amino)-1-cyclopropylethyl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)propan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-cyclopropyl-[1,1′-biphenyl]-2-carboxamide;

(S)-5-chloro-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-fluoro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)-5-bromo-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethoxy)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,5-dimethyl-2-morpholinobenzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-(dimethylamino)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)nicotinamide;

(S)-5-chloro-N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethyl-5-phenylthiazole-4-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-phenyl-1H-indole-3-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((4-fluorobenzyl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(quinazolin-2-yloxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((4-phenylpyrimidin-2-yl)oxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-((1-methyl-1H-benzo[d]imidazol-2-yl)oxy)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N -(1 -((5-chloropyridin-2-yl)oxy)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1 4(4-phenylpyrimidin-2-yl)amino)butan-2-yl)-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(quinazolin-2-ylamino)butan-2-yl) -[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4,6-dimethylpyrimidin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1 4(1-methyl-1H-benzo[d]imidazol-2-yl)amino)butan-2-yl)1,1′-biphenyl]-2-carboxamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5- (trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridazin-3-yl)amino)butan-2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)benzamide;

(S)—N-(1-(benzo[d]oxazol-2-ylamino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-(benzo[d]thiazol-2-ylamino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)-5-chloro-N-(1-((5-chloro-3-nitropyridin-2-yl)amino)butan-2-yl)-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1 4(5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,5-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,1-dimethyl-1H-indole-3-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N,2-dimethylquinoline-4-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)-3-methylbutan-2-yl)-N-methyl-2-(trifluoromethoxy)benzamide;

(S)-5-chloro-N-methyl-N-(1 4(6-methylpyridin-2-yl)amino)butan-2-yl)-2-(2H-1,2,3-triazol -2-yl)benzamide;

(S)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridin-3-yl)amino)butan-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((6-(trifluoromethyl)pyridin-3-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-(4-fluorobenzamido)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4-fluorobenzyl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-methyl-N-(3-methyl-1-(3-phenylureido)butan-2-yl) -N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((4-chlorophenyl)amino)-3-methylbutan-2-yl)-N-methyl-[1,1′-biphenyl]-2-carboxamide;

(S)—N-(1-((3-amino-5-chloropyridin-2-yl)amino)butan-2-yl)-5-chloro-N-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-N-(1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-(benzo[d]oxazol-2-ylamino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-(benzo[d]thiazol-2-ylamino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((5-chlorobenzo[d]oxazol-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(1-(quinoxalin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)-3-(2H -1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(3-methyl-1-((5-(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)-3-(2H -1,2,3-triazol-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5(trifluoromethyl)pyrazin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5(trifluoromethyl)pyridin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-N-(1-(quinazolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-ethyl-6-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1-((5(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N-(1-cyclopropyl-2-((5 -(trifluoromethyl)pyrimidin-2-yl)amino)ethyl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-N-(1-(quinolin-2-ylamino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1 -((1,5-naphthyridin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)-5-chloro-N-methyl-N-(1-(quinolin-2-ylamino)butan-2-yl)-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,3-dimethyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)quinoline-8-carboxamide;

(S)-6-chloro-N-methyl-N-(1 4(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)quinoline-8-carboxamide;

(S)-3-(dimethylamino)-N-methyl-N-(1 4(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N,6-dimethyl-N-(1-(methyl(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N-(1-((2-methoxyethyl)(5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)-N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(pyrimidin-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)—N-methyl-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)isoquinoline-1-carboxamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-N,4,5-trimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N-(1-((5-chloropyridin-2-yl)amino)butan-2-yl)-5-methoxy-N,4-dimethyl-2-(2H-1,2,3-triazol-2-yl)benzamide;

(S)—N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-(4,4,4-trifluoro-1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

(S)—N,6-dimethyl-3-(1H-1,2,4-triazol-1-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)—N,6-dimethyl-3-(1H-pyrazol-1-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide formic acid salt;

(S)-2-fluoro-N-methyl-6-(2H-1,2,3-triazol-2-yl)-N-(1-((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)benzamide; and

(S)-6-methoxy-N-methyl-3-(2H-1,2,3-triazol-2-yl)-N-(1((5-(trifluoromethyl)pyrimidin-2-yl)amino)butan-2-yl)picolinamide;

or a pharmaceutically acceptable salt or solvate thereof.

5. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: PIPER SANDLER FINANCE, LLC
To: INDIVIOR INC.; INDIVIOR UK LIMITED
Reel/Frame 074114/0582 →
SECURITY INTEREST Recorded Nov 13, 2024
From: INDIVIOR INC.; INDIVIOR UK LIMITED
To: PIPER SANDLER FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069254/0413 →
TERMINATION AND RELEASE OF SECURITY INTEREST Recorded Nov 11, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: INDIVIOR UK LIMITED (F/K/A RB PHARMACEUTICALS LIMITED)
Reel/Frame 069316/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: C4X DISCOVERY LIMITED
To: INDIVIOR UK LIMITED (CO.)
Reel/Frame 068680/0346 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Jun 30, 2021
From: INDIVIOR UK LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 056728/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2017
From: BLANEY, EMMA LOUISE; MARTIN, BARRIE PHILLIP; NOWAK, THORSTEN; WATSON, MARTIN JOHN
To: C4X DISCOVERY LIMITED
Reel/Frame 041747/0984 →
Priority Claims (1)
GB 1415569.1 · Sep 3, 2014 · national
Continuity (1)
Related Publication 20170291897A1 · Oct 12, 2017
Cited By (3)
US 12,201,634 US 12,378,254 US 12,441,709